Translation of aptamers toward clinical diagnosis and commercialization

Liu, Shan; Xu, Yixin; Xin, Jiang; Tan, Hong Qi; Ying, Binwu

doi:10.1016/j.bios.2022.114168

Cited by 38 publications

(18 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date a small number of commercially available aptamer-based diagnostic tests in the agricultural industry and for oncology is available 152 . Several diagnostic aptasensors for point-of-care testing are currently undergoing clinical trials and might result in widespread adaptation in clinical practice in the near future 198 . For therapeutic use, pegaptanib remains the only aptamer that has reached FDA approval and entered the market to date 29 .…”

Section: Discussionmentioning

confidence: 99%

Aptamers used for molecular imaging and theranostics - recent developments

Bohrmann¹,

Burghardt²,

Haynes³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Aptamers are single stranded oligonucleotides that fold into three dimensional structures and are able to recognize a variety of molecular targets. Due to the similarity to antibodies with regards to specificity and affinity and their chemical versatility, aptamers are increasingly used to create targeted probes for in vivo molecular imaging and therapy. Hence, aptamer-based probes have been utilized in practically all major imaging modalities such as nuclear imaging, magnetic resonance imaging, x-ray computed tomography, echography and fluorescence imaging, as well as newer modalities such as surface enhanced Raman spectroscopy. Aside from targeting, aptamers have been used for the creation of sensors that allow the localized detection of cellular markers such as ATP in vivo . This review focuses on in vivo studies of aptamer-based probes for imaging and theranostics since the comprehensive overview by Bouvier-Müller and Ducongé in 2018.

show abstract

Section: Discussionmentioning

confidence: 99%

Aptamers used for molecular imaging and theranostics - recent developments

Bohrmann¹,

Burghardt²,

Haynes³

et al. 2022

Theranostics

View full text Add to dashboard Cite

show abstract

“…Other qualities of avian IgYs, such as high robustness and low cost, as well as avoidance of animal bleeding, which offers better compliance with the “3Rs” ethical principle governing research with animals (Replacement—Reduction—Refinement) [ 68 , 106 ], may help IgYs to become more widely applied as biorecognition molecules in optical immunosensors. Moreover, in accordance with the recommendation of the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) [ 107 ], non-animal-derived antibodies might be eventually applied to immunosensors along with other products of synthetic biology, such as aptamers or molecular imprinted polymers [ 108 , 109 ], provided that current problems related to high cost, low availability, and often poor analytical features of the latter can be solved. Alternatively, combined use of totally-synthetic biorecognition molecules and traditional antibodies might prevail [ 110 , 111 ].…”

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Recent Developments in the Field of Optical Immunosensors Focusing on a Label-Free, White Light Reflectance Spectroscopy-Based Immunosensing Platform

Karachaliou

Koukouvinos

Goustouridis

et al. 2022

Sensors

View full text Add to dashboard Cite

Optical immunosensors represent a research field of continuously increasing interest due to their unique features, which can mainly be attributed to the high-affinity and specific antibodies they use as biorecognition elements, combined with the advantageous characteristics of the optical transducing systems these sensors employ. The present work describes new developments in the field, focusing on recent bioanalytical applications (2021–2022) of labeled and label-free optical immunosensors. Special attention is paid to a specific immunosensing platform based on White Light Reflectance Spectroscopy, in which our labs have gained specific expertise; this platform is presented in detail so as to include developments, improvements, and bioanalytical applications since the mid-2000s. Perspectives on the field are been briefly discussed as well, highlighting the potential of optical immunosensors to eventually reach the state of a reliable, highly versatile, and widely applicable analytical tool suitable for use at the Point-of-Care.

show abstract

“…[33] Although pegaptanib remains the only marketed clinical application at the moment, there are many other aptamerbased therapeutics in clinical trials. [63,[110][111][112] These aptamers target a variety of diseases, including myocardial ischemia, [113] metastatic renal cell carcinoma, [114] type 2 diabetes mellitus, [115] and thrombosis. [116] Apart from therapeutic usage, aptamers can also play an important role in disease diagnosis, for example, measuring the pulsatility of luteinising hormone, [117] analysing the level of various proteins in human serum [118] as well as detecting COVID-19 antigens.…”

Section: Clinical Applicationsmentioning

confidence: 99%

Chemical Modifications for a Next Generation of Nucleic Acid Aptamers

et al. 2022

View full text Add to dashboard Cite

In the past three decades, in vitro systematic evolution of ligands by exponential enrichment (SELEX) has yielded many aptamers for translational applications in both research and clinical settings. Despite their promise as an alternative to antibodies, the low success rate of SELEX (∼30 %) has been a major bottleneck that hampers the further development of aptamers. One hurdle is the lack of chemical diversity in nucleic acids. To address this, the aptamer chemical repertoire has been extended by introducing exotic chemical groups, which provide novel binding functionalities. This review will focus on how modified aptamers can be selected and evolved, with illustration of some successful examples. In particular, unique chemistries are exemplified. Various strategies of incorporating modified building blocks into the standard SELEX protocol are highlighted, with a comparison of the differences between pre‐SELEX and post‐SELEX modifications. Nucleic acid aptamers with extended functionality evolved from non‐natural chemistries will open up new vistas for function and application of nucleic acids.

show abstract

Translation of aptamers toward clinical diagnosis and commercialization

Cited by 38 publications

References 159 publications

Aptamers used for molecular imaging and theranostics - recent developments

Aptamers used for molecular imaging and theranostics - recent developments

Recent Developments in the Field of Optical Immunosensors Focusing on a Label-Free, White Light Reflectance Spectroscopy-Based Immunosensing Platform

Chemical Modifications for a Next Generation of Nucleic Acid Aptamers

Contact Info

Product

Resources

About